FindTrial
Sign In

To see the effectiveness of injection ropivacaine hydrochloride (0.5%) vs injection levobupivacaine hydrochloride (0.5%) in below knee surgeries by peripheral nerve stimulator guided popliteal nerve block .

To evaluate the effectiveness of injection ropivacaine hydrochloride (0.5%) vs injection levobupivacaine hydrochloride (0.5%) in peripheral nerve stimulator guided popliteal nerve block for below knee surgeries. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064646
Enrollment
50
Registered
2024-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S829- Unspecified fracture of lower leg

Interventions

Intervention1: ROPIVACAINE: inj.Ropivacaine hydrochloride (0.5%) 30cc. Intervention2: LEVOBUPIVACAINE: inj. Levobupivacaine hydrochloride (0.5%) 30cc. Intervention3: Inj. ROPIVACAINE: inj. Ropivacaine

Sponsors

UDAYKUMAR GADHETHARIYA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having ASA(American society of anaesthesiology) physical status I,II and III of either gender. Patients posted for below knee surgeries.

Exclusion criteria

Exclusion criteria: Patient who will not given written informed consent. Patients with known hypersensitivity to study drugs. Patients with altered coagulation profile, h/o psychological or neurological disorder. Patients converted to general anaesthesia due to uneffectiveness of study drugs

Design outcomes

Primary

MeasureTime frame
To estimate the onset & duration of sensory blockade in both the groups. To estimate the onset & duration of motor blockade in both the groups. To estimate the duration of post operative analgesia in both the groups. Timepoint: AT THE END OF 15 MONTHS—

Secondary

MeasureTime frame
To assess the changes in hemodynamic parameters in both the groups. To assess the perioperative adverse effects & complications if any in both the groups. Timepoint: AT THE END OF 15 MONTHS—

Countries

India

Contacts

Public ContactUDAYKUMAR GADHETHARIYA

GOVERNMENT MEDICAL COLLEGE, BHAVNGAR

drshilpadoshi@yahoo.in9428810763

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026